healthcare Tech Sees Major Investment, Shifts as Best Buy Exits At-Home Care
A surge of investment and strategic repositioning are reshaping the healthcare technology landscape, with significant funding rounds for AI-driven solutions and a notable divestiture from a major retailer. These developments, announced on June 25, 2025, signal a continued focus on streamlining processes and adapting to evolving market demands within the industry.
Mandolin Secures $40 Million to automate specialty Drug Management
Mandolin, a company leveraging artificial intelligence to simplify the complex world of specialty drug administration, has raised $40 million in combined seed and Series A funding. The investment will fuel the expansion of its platform, which utilizes AI agents to manage everything from initial intake and benefits verification to prior authorizations and revenue cycle management (RCM). According to a company release, this funding aims to “obliterate specialty drug paperwork,” a significant pain point for healthcare providers and patients alike.
The increasing complexity of specialty drug protocols has created a substantial administrative burden, and MandolinS approach promises to alleviate this through automation and clever workflow management. .
Best Buy Reverses Course, Sells Current Health Back to Founder
In a surprising move, Best Buy has sold Current Health, its care-at-home technology company, back to its co-founder and former CEO, Christopher McGhee. the sale comes less than four years after Best Buy acquired Current Health for $400 million.
One analyst noted that the divestiture reflects a broader reassessment of Best Buy’s healthcare strategy. While the company initially saw potential in expanding into in-home care, the challenges of scaling such a business and integrating it with its core retail operations appear to have proven significant. The financial terms of the sale were not disclosed.
BlueBriX Gains $15 Million for AI Workflow Orchestration
BlueBriX, a health IT vendor, announced a $15 million investment to scale its agentic AI workflow orchestration platform for value-based care. The funding will support the continued progress and deployment of its technology, which aims to streamline complex healthcare processes and improve outcomes.
The company’s platform focuses on automating and coordinating workflows within value-based care models, where providers are incentivized to deliver high-quality, cost-effective care. This investment underscores the growing demand for AI-powered solutions that can help healthcare organizations navigate the complexities of these evolving payment models.
Veradigm Pursues SEC Compliance and Relisting
Veradigm provided a business and financial update on June 25, 2025, outlining its plans to bring its filings with the Securities and Exchange Commission (SEC) up to date.The company anticipates completing this process sometime next year, after which it will seek to relist its stock.
A senior official stated that the company is committed to regaining compliance and restoring investor confidence. The delay in filings has been a significant challenge for Veradigm, and its successful resolution will be crucial for its future growth and stability.
These developments collectively demonstrate a dynamic period for healthcare technology, characterized by significant investment in AI-driven solutions, strategic shifts in market positioning, and a continued focus on improving efficiency and outcomes.
